Clinical Trial: Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07513324) titled 'Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)' on April 01.

Brief Summary: The purpose of this study is to assess risk for HPV driven oropharyngeal cancers by using HPV blood tests and clinical features (such as tumor stage and smoking status) to determine appropriate treatment to improve survival outcomes in participants with stage I, II, or III, HPV-associated oropharyngeal (tongue base or tonsil) squamous cell carcinoma,.

Study Start Date: May 01

Study Type: INTERVENTIONAL

Condition: HPV-positive Oropharyngeal Squamous Cell Carcinoma Oropharyngeal Squamous...